<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 4, 2019 (HealthDay News) — Maintenance therapy with olaparib is associated with improved progression-free survival in metastatic pancreatic cancer patients with a germline BRCA1<\/i> and\/or BRCA2<\/i> mutation (gBRCAm), according to a study presented at the annual meeting of the American Society for Clinical Oncology, held from May 31 to June 4 in Chicago.<\/p>\n
Hedy L. Kindler, M.D., from the University of Chicago, and colleagues conducted a randomized trial involving 247 patients with a gBRCAm and pancreatic adenocarcinoma who received \u226516 weeks of platinum-based chemotherapy (PBC) for metastatic disease without progression. A total of 151 patients received olaparib or placebo (90 and 61 patients, respectively).<\/p>\n
The researchers found that progression-free survival was significantly improved with olaparib versus placebo, with 104 events (median progression-free survival, 7.4 versus 3.8 months; hazard ratio, 0.53; 95 percent confidence interval, 0.35 to 0.82); the benefit was consistent regardless of response to prior PBC (complete\/partial: hazard ratio, 0.62; stable disease: hazard ratio, 0.50). At each time point from six to 24 months, the percentage of progression-free patients was higher in the olaparib versus placebo arm (six months: 53.0 versus 23.0 percent; 12 months: 33.7 versus 14.5 percent; 18 months: 27.6 versus 9.6 percent; 24 months: 22.1 versus 9.6 percent). At the interim overall survival analysis at 46 percent maturity, the hazard ratio was 0.91 (95 percent confidence interval, 0.56 to 1.46).<\/p>\n
“Roughly one in five patients responded to olaparib for a median of two years, which is truly remarkable for metastatic pancreatic cancer,” Kindler said in a statement.<\/p>\n
Several authors disclosed financial ties to AstraZeneca, which manufactures olaparib and partially funded the study.<\/p>\n
Press Release<\/a><\/p>\n